{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04449874","nct_id":"NCT04449874","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04449874. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.\n\nParticipants with select solid tumors will be treated with GDC-6036 PO QD in Stage II.","label":"Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)","type":"EXPERIMENTAL"},{"description":"Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.","label":"Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)","type":"EXPERIMENTAL"},{"description":"Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.","label":"Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)","type":"EXPERIMENTAL"},{"description":"Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.","label":"Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)","type":"EXPERIMENTAL"},{"description":"Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.","label":"Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)","type":"EXPERIMENTAL"},{"description":"Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.\n\nParticipants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II.","label":"Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)","type":"EXPERIMENTAL"},{"description":"Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.\n\nParticipants with select solid tumors will be treated with GDC-6036 in combination with inavolisib PO in Stage II.","label":"Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer","Colorectal Cancer","Advanced Solid Tumors"],"enrollment":{"count":498,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"GDC-6036","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Cetuximab","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Erlotinib","otherNames":[],"type":"DRUG"},{"name":"GDC-1971","otherNames":[],"type":"DRUG"},{"name":"Inavolisib","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Genentech, Inc.","official_title":"A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants With Adverse Events (AEs)","timeFrame":"From Cycle 1 Day 1 until 28 days after the final dose (or as specified in the protocol). A cycle is 21 days."},{"measure":"Percentage of Participants With Dose-Limiting Toxicities (DLTs)","timeFrame":"From Cycle 1 Day 1 through Day 21. A cycle is 21 days."}],"references":[{"citation":"Sacher AG, Miller WH Jr, Patel MR, Paz-Ares L, Santoro A, Ahn MJ, Dziadziuszko R, Freres P, Luo J, Bowyer S, Desai J, Markman B, De Miguel M, Deva S, Falcon A, Alonso G, Guedes JD, Kim SH, Krebs MG, Laurie SA, Massarelli E, Medina L, Prenen H, Amatu A, Van Dongen M, Choi Y, Hou X, Qi T, Lin MT, Koli K, Mayo MC, Yau KK, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Lorusso P; GO42144 Investigator Study group; GO42144 Investigator Study Group. Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study. J Clin Oncol. 2025 Oct 20;43(30):3249-3253. doi: 10.1200/JCO-25-00040. Epub 2025 Jul 9.","pmid":"40632992","type":"DERIVED"},{"citation":"Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5.","pmid":"38052910","type":"DERIVED"},{"citation":"Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810.","pmid":"37611121","type":"DERIVED"}],"start_date":{"date":"2020-07-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","url":"https://clinicaltrials.gov/study/NCT04449874"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04449874"}